Correspondence 0001104659-24-005876 from ArriVent Biopharma, Inc. (AVBP) (CIK 0001868279) (AVBP)
ArriVent Biopharma, Inc. (AVBP) (CIK 0001868279)
Date: Jan. 23, 2024 · CIK: 0001868279 · Accession: 0001104659-24-005876
AI Filing Summary & Sentiment
File numbers found in text: 333-276397
Letter
ArriVent BioPharma, Inc.
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
January 23, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Christopher Edwards and Suzanne Hayes
Re: ArriVent BioPharma, Inc.
Registration Statement on Form S-1, as amended (File No. 333-276397)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, ArriVent BioPharma, Inc. (the “Company”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended to date, the “Registration Statement”) and declare the Registration Statement effective as of 5:00 p.m. Eastern time, on January 25, 2024, or as soon thereafter as possible, or at such other time as its legal counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (“Mintz”), may request by telephone to the staff of the Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with John Rudy of Mintz at (617) 348-3050 or, in his absence, Nishant Dharia of Mintz at (212) 692-8174.
Under separate cover, you will receive today a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
Very truly yours,
ArriVent BioPharma, Inc.
Show Raw Text
CORRESP
1
filename1.htm
ArriVent BioPharma, Inc.
18 Campus Boulevard,
Suite 100
Newtown Square, PA 19073
January 23, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Christopher Edwards and Suzanne Hayes
Re: ArriVent BioPharma, Inc.
Registration Statement on Form S-1, as
amended (File No. 333-276397)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and
Regulations under the Securities Act of 1933, as amended, ArriVent BioPharma, Inc. (the “Company”) hereby requests
that the U.S. Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced
Registration Statement on Form S-1 (as amended to date, the “Registration Statement”) and declare the Registration
Statement effective as of 5:00 p.m. Eastern time, on January 25, 2024, or as soon thereafter as possible, or at such other time
as its legal counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (“Mintz”), may request by telephone to the
staff of the Commission.
Once the Registration Statement has been declared
effective, please orally confirm that event with John Rudy of Mintz at (617) 348-3050 or, in his absence, Nishant Dharia of Mintz
at (212) 692-8174.
Under separate cover, you will receive today
a letter from the managing underwriters of the proposed offering joining in the Company’s request for acceleration of the effectiveness
of the Registration Statement.
Very truly yours,
ArriVent BioPharma, Inc.
/s/ Zhengbin (Bing) Yao
By: Zhengbin (Bing) Yao, Ph.D.
Title: Chairman, Chief Executive Officer
and Director
cc: Winston Kung, MBA, Chief Financial Officer and Treasurer, ArriVent
BioPharma, Inc.
James Kastenmayer, Ph.D.,
JD, General Counsel, ArriVent BioPharma, Inc.
John
Rudy, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Alison Haggerty, Latham & Watkins LLP
Nathan Ajiashvili, Latham & Watkins LLP